Here, we show that inhibition of anti‐apoptotic Bcl‐2 family members together with activation of LXRs causes synthetic lethality in a variety of solid tumors, including colorectal carcinoma, melanoma, and glioblastoma. Here, BCL2 is linked to melanoma.